FDA
-
-
-
-
-
-
-
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Stu
-
-
-
-
-
-
-
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
-
-
-
-
-
-
-
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
-
-
-
-
-
-
-
Aptevo Therapeutics Reports First Quarter 2018 Financial Results
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

